帕博西尼治疗伴CDK4通路基因异常的晚期肢端黑色素瘤
主要终点ORR为20.0%(3例8周时肿瘤缩小,1例确认部分缓解),中位PFS 2.2个月,中位OS 9.5个月;常见治疗相关不良事件为白细胞减少、中性粒细胞减少和乏力。MCM7扩增或高蛋白表达与临床获益相关,JAK-STAT通路可能参与作用机制。
要点
- 帕博西尼单药在CDK4通路异常的晚期肢端黑色素瘤中显示初步疗效和可接受的安全性。
- MCM7扩增或高蛋白表达的患者更可能从帕博西尼治疗中获益。
- JAK2缺失和SH2B3扩增见于未获得临床获益的患者,JAK-STAT通路可能参与机制。
核心结论
- 帕博西尼单药在伴CDK4通路异常的晚期肢端黑色素瘤患者中显示出初步疗效和可接受的安全性。
- MCM7扩增或高蛋白表达的患者更倾向于从帕博西尼治疗中获益。
- JAK-STAT通路可能在帕博西尼治疗肢端黑色素瘤的作用机制中发挥作用。
研究设计与样本
- 帕博西尼口服125 mg,每28天周期第1–21天给药。
- 主要终点为总缓解率(ORR),次要终点为无进展生存期(PFS)、总生存期(OS)和治疗相关不良事件(TRAEs)。
- 对9例可获取福尔马林固定石蜡包埋样本的患者进行全外显子测序和多重免疫组化分析,以探索帕博西尼反应的预测生物标志物。
主要发现
- 截至数据截止日期,1例患者仍在接受治疗。
- 中位PFS为2.2个月(范围:1.5–13.3个月;95%CI:1.9–2.5),中位OS为9.5个月(范围:2.6–14.1个月;95%CI:5.7–13.4)。
- 8例患者因疾病进展死亡。
- 未达到任何临床获益(CB)的患者中观察到显著的JAK2缺失和SH2B3扩增;MCM7扩增或蛋白表达水平与CB相关。
关键数值与推荐
- 最常见TRAEs为白细胞减少(87%;III/IV级,27%)、中性粒细胞减少(80%;III/IV级,27%)和乏力(53%;III/IV级,7%)。
临床怎么用
- 对于伴CDK4通路基因异常的晚期肢端黑色素瘤患者,帕博西尼单药可考虑作为一种治疗选择,但需注意血液学毒性。
- MCM7扩增或高蛋白表达可能作为帕博西尼获益的预测生物标志物,JAK2缺失和SH2B3扩增可能提示不获益。
局限性
- 生物标志物分析仅基于9例患者的available样本,探索性结果需更大样本确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic aberrations in the cyclin-dependent kinase (CDK)4 pathway occur in 82% of patients with acral melanoma (AM), which is the predominant subtype of melanoma in China. We aimed to evaluate the anti-tumour activity of palbociclib, a selective CDK4/6 inhibitor, in patients with advanced AM with CDK4 pathway gene aberrations. METHODS: In this phase II trial, patients with advanced AM with CDK4 or/and CCND1 gain or/and CDKN2A loss were treated with oral palbociclib (125 mg) on days 1-21 of a 28-day cycle. The primary end-point was overall response rate (ORR). Secondary end-points were progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). Whole-exome sequencing and multiplex immunohistochemistry of the available formalin-fixed, paraffin-embedded samples of nine patients were analysed to explore the predictive biomarkers of palbociclib response. RESULTS: Fifteen patients were enrolled. Three (20.0%) patients achieved tumour shrinkage at 8 weeks, including one with confirmed partial response. At data cut-off date, treatment was ongoing for one patient. The median PFS was 2.2 mo (range: 1.5-13.3 mo; 95% confidence interval [CI]: 1.9-2.5), and the median OS was 9.5 mo (range: 2.6-14.1 mo, 95% CI: 5.7-13.4). Eight patients died due to disease progression. The most common TRAEs were leukopenia (87%; Grade III/IV, 27%), neutropenia (80%; grade III/IV, 27%), and fatigue (53%; grade III/IV, 7%). Significant JAK2 deletions and SH2B3 amplifications were observed in patients who did not achieve any clinical benefit (CB) with palbociclib treatment. MCM7 amplification or protein expression level was found to be associated with CB. CONCLUSIONS: Palbociclib monotherapy demonstrated preliminary efficacy and an acceptable safety profile in advanced AM patients with CDK4 pathway aberrations. Patients with amplification or high protein levels of MCM7 were more prone to benefit from palbociclib. The JAK-STAT pathway might play a role in the mechanism of action of palbociclib in AM. TRIAL REGISTRATION NUMBER: NCT03454919. THE DATE OF REGISTRATION: March 6, 2018.
引用
- Mao L, Dai J, Cao Y, et al. Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway. Eur J Cancer. 2021. PMID: 33770575. doi:10.1016/j.ejca.2021.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。